Sir, firstly on Poviztra, where patent expiry is sort of in March '26 anticipated. So from that perspective, how does this deal help? Because in this case, we are not going to use Innovators brand. And do we have area demarcation in terms of certain regions or areas where there will be sort of exclusivity for Emcure or certain areas where Novo Nordisk will be selling? If you can clarify these two please?
Got it. And just secondly, just in terms of is there any area demarcation or certain areas to be addressed by you or you will be sort of able to sell even where Novo Nordisk is selling?